Shares of Novo Nordisk A/S (NVO) plummeted 5.02% in intraday trading on Thursday, following a significant downgrade from HSBC. The global banking giant revised its rating on the Danish pharmaceutical company from Buy to Hold, triggering a sell-off among investors.
HSBC not only downgraded Novo Nordisk but also drastically reduced its price target for the stock. The new target was set at $57, a substantial decrease from the previous target of $102. This adjustment represents a nearly 44% reduction in HSBC's valuation of the company, contributing to the sharp decline in Novo Nordisk's stock price.
The rationale behind HSBC's decision appears to be linked to concerns about Novo Nordisk's position in the obesity market. According to the firm, their previous thesis that Novo would regain obesity market share is no longer supported. This shift in perspective suggests that HSBC analysts have reassessed the company's growth prospects in this key therapeutic area, leading to a more cautious stance on the stock.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。